|
Mr. Changfa Li Chairman and President Shanghai Hualian Pharmaceuticals
|
Changfa Li is currently the Chairman and President of Shanghai Hualian Pharmaceutical Co., Ltd. Mr. Li was born in 1952 and graduated in 1982 from China Eastern Institute of Technology as a BS in bio-engineering. After he joined Shanghai #12 Pharmaceutical Factory (later became Shanghai Hualian Pharmaceutical Co., Ltd.), he was quickly promoted to the general manager of the company. In 1993, Mr. Li became the Chairman and president of Shanghai Hualian Pharmaceuticals. In 1995, Mr. Li received his MBA from Tianjin University. During his nineteen years tenure at Hualian, he managed the company annual growth of 20% since 1993. And Hualian Pharmaceutical Co., Ltd. became one of the top 50 pharmaceutical companies in China. Mr. Changfa Li has received numerous awards, including the Outstanding Young Entrepreneur Award and two consecutive year with The Most Reliable Business Executive Award, both from the Shanghai City. In 2001, Mr. Li became the member of Shanghai Life Sciences Committee of Chinese Academy of Sciences. One of his literature, titled "Business Owner", was awarded the first rank by Chinese Outstanding Scholarship Literature Committee. 中国制药业面临的挑战 一、中国市场潜力很大 ● 工业销售、出口● 商业销售● 市场容量大● 市场市值小中国的医药市场又是如何? 发展趋势的主要影响因素、三医改革角色 ◆ 医疗安全保障(基本日常)◆ 临床→医药分家
二、中国有几千家制药企业 他们的组成结构及在医药市场的地位又是如何? 国内企业、合资企业、进口企业 ▲ 市场份额
三、非合资性的制药企业在发展出路上不同反映 a. 在改制方面的反映b. 在技术开发方面的反映(二难)c. 在市场开发方面的反映d. 在资产重组方面的反映
四、在中国市场新品销售的不成文的惯例 制造商所得 =批发价×(20%~30%)★ 对新品开发的影响★ 对市场营销的影响
|